Publications by authors named "Ivette Revollo"

Claim this Profile
T
Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial.
Richard Furie, Jürgen Steffgen, Nora Fagan, Juanita Romero-Diaz, Yingyos Avihingsanon, Ivette Revollo

Lupus· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
David R Jayne, Jürgen Steffgen, Juanita Romero-Diaz, Ingeborg Bajema, Dimitrios T Boumpas, Ivette Revollo

Arthritis Rheumatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Arne Ring, Andreas Port, E Ulrike Graefe-Mody, Ivette Revollo, Mario Iovino

Br J Clin Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pro- and anti-apoptotic dual functions of the C5a receptor: involvement of regulator of G protein signaling 3 and extracellular signal-regulated kinase.
Hiroshi Nishiura, Hideo Nonaka, Ivette S Revollo, Umeko Semba, Ying Li

Lab Invest· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis